Giampiero Girolomoni1, Thomas Luger2, Audrey Nosbaum3, David Gruben4, William Romero5, Lyndon John Llamado6, Marco DiBonaventura7. 1. Department of Medicine, Università di Verona, Verona, Italy. 2. Department of Dermatology, University of Münster, Münster, Germany. 3. Department of Clinical Immunology and Allergy, Lyon-Sud University Hospital, Pierre-Bénite, France. 4. Pfizer Inc., Groton, CT, USA. 5. Pfizer Ltd., Tadworth, Surrey, UK. 6. Pfizer Inc., Makati, Philippines. 7. Pfizer Inc., New York, NY, USA. marco.dibonaventura@pfizer.com.
Abstract
INTRODUCTION: Atopic dermatitis (AD) is a common inflammatory disease of the skin, which may have a substantial impact on patients' health-related quality of life (HRQoL). The aim of this study was to quantify the economic burden (direct and indirect costs) of moderate-to-severe AD and evaluate the prevalence and impact of psychosocial comorbidities among patients in the European Union-5 (France, Germany, Italy, Spain, and the UK). METHODS: Data were analyzed from the 2017 EU5 National Health and Wellness Survey. Respondents with a physician diagnosis of AD/eczema who were considered to have moderate-to-severe AD based on a Dermatology Life Quality Index (DLQI) score ≥ 6 were included. Direct costs, indirect costs, and psychosocial comorbidities (sleep difficulties and anxiety based on self-report, depression based on the Patient Health Questionnaire-9) were reported descriptively. Generalized linear models were used to examine the relationship between psychosocial comorbidities and health outcomes (the Short Form-36 version 2 [SF-36v2], EuroQoL 5-dimension 5-level, Work Productivity and Activity Impairment questionnaire, and healthcare resource utilization). RESULTS: Overall, 1014 patients were included in the analysis. Total annual direct costs ranged from €2242 to €6924 and total annual indirect costs ranged from €7277 to €14,236, depending on the level of disease severity. Sleep difficulties, anxiety, and depression were reported by 61.6%, 52.7%, and 75.8% of patients, respectively. These comorbidities were significantly associated with reduced physical and mental component summary scores from SF-36v2 and increased overall work impairment (p < 0.05 for all). CONCLUSIONS: A significant economic burden was observed for patients with moderate-to-severe AD. Sleep difficulties, depression, and anxiety were observed in more than half of moderate-to-severe AD patients and were significantly associated with decrements in HRQoL and with work-related impairment. Reducing the burden of these psychosocial comorbidities in AD could have significant benefit to patients and society.
INTRODUCTION:Atopic dermatitis (AD) is a common inflammatory disease of the skin, which may have a substantial impact on patients' health-related quality of life (HRQoL). The aim of this study was to quantify the economic burden (direct and indirect costs) of moderate-to-severe AD and evaluate the prevalence and impact of psychosocial comorbidities among patients in the European Union-5 (France, Germany, Italy, Spain, and the UK). METHODS: Data were analyzed from the 2017 EU5 National Health and Wellness Survey. Respondents with a physician diagnosis of AD/eczema who were considered to have moderate-to-severe AD based on a Dermatology Life Quality Index (DLQI) score ≥ 6 were included. Direct costs, indirect costs, and psychosocial comorbidities (sleep difficulties and anxiety based on self-report, depression based on the Patient Health Questionnaire-9) were reported descriptively. Generalized linear models were used to examine the relationship between psychosocial comorbidities and health outcomes (the Short Form-36 version 2 [SF-36v2], EuroQoL 5-dimension 5-level, Work Productivity and Activity Impairment questionnaire, and healthcare resource utilization). RESULTS: Overall, 1014 patients were included in the analysis. Total annual direct costs ranged from €2242 to €6924 and total annual indirect costs ranged from €7277 to €14,236, depending on the level of disease severity. Sleep difficulties, anxiety, and depression were reported by 61.6%, 52.7%, and 75.8% of patients, respectively. These comorbidities were significantly associated with reduced physical and mental component summary scores from SF-36v2 and increased overall work impairment (p < 0.05 for all). CONCLUSIONS: A significant economic burden was observed for patients with moderate-to-severe AD. Sleep difficulties, depression, and anxiety were observed in more than half of moderate-to-severe ADpatients and were significantly associated with decrements in HRQoL and with work-related impairment. Reducing the burden of these psychosocial comorbidities in AD could have significant benefit to patients and society.
Entities:
Keywords:
Anxiety; Atopic dermatitis; Depression; Health-related quality of life; Healthcare resource utilization; Sleep difficulties; Work impairment
Authors: Jacob P Thyssen; Andreas W Brenneche; Maria E Madsen; Mikkel H Pedersen; Dennis J Trangbaek; Christian Vestergaard Journal: Acta Derm Venereol Date: 2021-09-03 Impact factor: 3.875
Authors: Yoshie Umehara; Chanisa Kiatsurayanon; Juan Valentin Trujillo-Paez; Panjit Chieosilapatham; Ge Peng; Hainan Yue; Hai Le Thanh Nguyen; Pu Song; Ko Okumura; Hideoki Ogawa; François Niyonsaba Journal: Biomedicines Date: 2021-02-25
Authors: M J Cork; A McMichael; J Teng; H Valdez; R Rojo; G Chan; F Zhang; D E Myers; M DiBonaventura Journal: J Eur Acad Dermatol Venereol Date: 2021-12-04 Impact factor: 9.228
Authors: S Ständer; N Bhatia; M J Gooderham; J I Silverberg; J P Thyssen; P Biswas; M DiBonaventura; W Romero; S A Farooqui Journal: J Eur Acad Dermatol Venereol Date: 2022-05-06 Impact factor: 9.228